Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Multi-component Intervention for Diabetes in Adults With Serious Mental Illness (MIDAS)

15 settembre 2021 aggiornato da: Dilip V. Jeste, University of California, San Diego

Multi-component Intervention for Diabetes in Adults With Serious Mental Illness (MIDAS)

Persons with schizophrenia and other serious mental illnesses have a high risk for type 2 diabetes and an increased risk of premature mortality compared to the general population. The goals of the proposed study are to implement a multimodal lifestyle intervention to reduce that risk in these individuals living in residential care facilities, a common housing modality for people with serious mental illnesses. If successful, this intervention will lead to reduction in excess medical comorbidity and mortality in persons with serious mental illnesses.

Panoramica dello studio

Descrizione dettagliata

Serious mental illnesses (SMI), including schizophrenia, bipolar disorder, and schizoaffective disorder, are associated with increased medical comorbidity and premature mortality from diabetes and cardiovascular disease. Unhealthy lifestyles, including energy-dense (obesogenic) diet, sedentary behavior, and cigarette smoking are important risk factors for diabetes and accelerated biological aging. All of these risk factors are potentially modifiable. There is considerable literature documenting the effectiveness of strategies to prevent and manage diabetes in the general population; yet, these interventions are rarely offered to people with SMI. Residential Care Facilities (RCFs), called Board-and-Care Homes in California, are a common housing modality for patients with SMI; they provide a venue that can maximize efficiency and sustainability of a lifestyle intervention. The goals of the proposed four-year study are to tailor a multi-component intervention to this high-risk group. The study will be a hybrid effectiveness-implementation (Hybrid Type 1) trial of a Multi-component Intervention for Diabetes risk reduction in Adults with SMI (MIDAS) in licensed RCFs in San Diego county. As a Hybrid Type 1 study, the primary emphasis will be on determining the effectiveness of the intervention to achieve desired health outcomes while also systematically collecting data on its implementation within RCFs that will inform implementation strategy refinement. Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction. The investigators will employ a modified cluster-randomized stepped wedge and adaptive trial design involving 210 residents with SMI and 120 staff members from 12 RCFs. The RCFs will be divided randomly into four cohorts of three RCFs each. Each cohort will be tested over a 15-month period that includes three phases: a three-month initial control phase (no intervention, from baseline month 0 to end of month 3), a six-month intervention phase (months 4 through 9), and a six-month follow-up phase (no intervention, months 10 through 15). All the study participants will be assessed quarterly during the 15-month period. Our investigators will train RCF staff (especially the Activity Director and cook) to increase physical activity and reduce smoking, and to implement healthful dietary modifications among the residents, using evidence-based interventions. During the intervention phase, the RCF Activity Director will conduct twice-weekly manualized group sessions on education about diabetes, nutrition, exercise, and smoking cessation/reduction, to deliver a multi-component group intervention. We will also explore if there are improvements in blood-based research biomarkers of insulin resistance and inflammation in the RCF residents with SMI. This project is responsive to RFA-MH-17-608, and related to NIMH Strategic Objective #3.3B: testing interventions for effectiveness in community practice settings. If successful, MIDAS will be sustained and disseminated, and would lead to reduction in excess medical comorbidity and mortality associated with SMI.

Tipo di studio

Interventistico

Iscrizione (Anticipato)

210

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Dilip V Jeste, MD
  • Numero di telefono: (858) 534-4020
  • Email: djeste@ucsd.edu

Backup dei contatti dello studio

  • Nome: Danielle K Glorioso, LCSW
  • Numero di telefono: (858) 246-0767
  • Email: dglorioso@ucsd.edu

Luoghi di studio

    • California
      • La Jolla, California, Stati Uniti, 92093
        • Reclutamento
        • University of California, San Diego Division of Geriatric Psychiatry
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Dilip V Jeste, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 65 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Participants: A total of 12 RCFs (30 to 45 beds each), 210 resident participants, and 120 staff members (1 manager, 2 activity directors, 1 cook, and 6 other staff members per facility) will be enrolled.

Inclusion and Exclusion Criteria:

Residential Care Facilities (RCFs):

Inclusion Criteria:

  1. Licensed by California Division of Social Services' Community Care Licensing
  2. Serves only individuals with SMI
  3. Has >15 residents currently living in the facility
  4. Willing to participate

Staff Participants:

Inclusion Criteria:

  1. Age >21 years
  2. Fluent in English
  3. Written informed consent to participate

Exclusion Criteria:

(1) Plans to leave the RCF during the next year.

Resident Participants:

Inclusion Criteria:

  1. Age 18 - 65 years
  2. Chart diagnosis of an SMI, mainly schizophrenia, schizoaffective disorder, or bipolar disorder
  3. Current treatment with antipsychotics
  4. Fluent in English
  5. Written informed consent to participate in this study

Exclusion Criteria:

  1. Chart diagnosis of dementia or intellectual disability disorder
  2. Active substance abuse (non-tobacco)
  3. Medical problems that interfere with ability to complete assessments and intervention

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Control Phase
3-month initial control phase (no intervention, month 1-3)
Sperimentale: Intervention Phase
6-month intervention phase - MIDAS Intervention Delivered. Followed by 6-month follow-up phase (no intervention, months 10-15).
Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Body Mass Index (BMI in kg/m^2)
Lasso di tempo: Baseline to 9 months and sustained at 15 months
Change in Body Mass Index
Baseline to 9 months and sustained at 15 months
Waist Circumference
Lasso di tempo: Baseline to 9 months and sustained at 15 months
Change in Waist Circumference
Baseline to 9 months and sustained at 15 months
Fasting Glucose
Lasso di tempo: Baseline to 9 months and sustained at 15 months
Change in Fasting Glucose
Baseline to 9 months and sustained at 15 months
Hemoglobin A1c or HbA1c
Lasso di tempo: Baseline to 9 months and sustained at 15 months
Change in Hemoglobin A1c or HbA1c
Baseline to 9 months and sustained at 15 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Diet/Nutrition - Plasma Carotenoid Levels
Lasso di tempo: Baseline to 9 months and sustained at 15 months
Plasma Carotenoid levels reflect changing dietary vegetable and fruit intake.Nutrition Data Systems for REsearch (NDS-R) Protocol
Baseline to 9 months and sustained at 15 months
Diet/Nutrition - Serum Lipid Levels
Lasso di tempo: Baseline to 9 months and sustained at 15 months
Plasma Carotenoid levels reflect changing dietary vegetable and fruit intake.
Baseline to 9 months and sustained at 15 months
Objective Measure of Physical Activity
Lasso di tempo: Baseline to 9 months and sustained at 15 months
For 7 days during each assessment period, participants will wear the GT3X+ Actigraph, which measures movement and intensity of activity, and has good validation with VO2max. It provides estimates of activity by seconds, that can be categorized into minutes spent in sedentary, light, moderate, and vigorous activity using calibration thresholds.
Baseline to 9 months and sustained at 15 months
Smoking - Expired Breath Carbon Monoxide (CO) Levels
Lasso di tempo: Baseline to 9 months and sustained at 15 months
Change in Smoking - Objective Measure of Cigarette Use: Expired Breath Carbon Monoxide (CO) level (parts per million) is measured with a handheld device. CO monitoring is used primarily as a check on recent smoking, though it has also been used to indicate reductions in smoking.
Baseline to 9 months and sustained at 15 months
Smoking - Change in Smoking through Recall
Lasso di tempo: Baseline to 9 months and sustained at 15 months
Change in Smoking - Quantity and frequency of cigarette use for the prior week using a timeline followback procedure. Smoking reduction calculated by % change in average cigarettes/day across assessments.
Baseline to 9 months and sustained at 15 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

28 dicembre 2018

Completamento primario (Anticipato)

31 maggio 2022

Completamento dello studio (Anticipato)

31 maggio 2022

Date di iscrizione allo studio

Primo inviato

5 luglio 2018

Primo inviato che soddisfa i criteri di controllo qualità

9 agosto 2018

Primo Inserito (Effettivo)

13 agosto 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 settembre 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 settembre 2021

Ultimo verificato

1 settembre 2021

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi